Autor:	Shiosaki, Kazumi
Zdroj:	Expert Opinion on Therapeutic Patents; November 1994, Vol. 4 Issue: 11 p1361-1365, 5p
Abstrakt:	Data from animal models indicate that endothelin (ET) receptor antagonists may have therapeutic utility in hypertension, myocardial infarction and subsequent reperfusion injury, acute renal failure and asthma. Selective antagonists for the two receptor subtypes (ETaand ETb) are now available. Nonpeptide ETA-selective antagonists are now available and have the potential of developing into orally active agents in clinical studies.
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu